Skip to content
DataLookout
Menu

NCT03309033

Extended Follow-up of Women Who Received One, Two, and Three Doses of the HPV Vaccine in the Costa Rica Vaccine Trial (CVT), ESCUDDO-CVT Study

StatusActive, Not Recruiting
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 281 versions: 34 with changes below, 16 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment increased: 1 → 946 participants
  2. Notable Enrollment reduced: 946 → 1 participants
  3. Notable Eligibility criteria expanded, about 2 words
  4. Minor Study completion pushed from Feb 28, 2026 to Dec 28, 2028v276
  5. Minor Enrollment target: estimated 991 to confirmed 946
    • Primary completion date changed from estimate of Feb 28, 2026 to Mar 5, 2026
    • Study completion date: Feb 28, 2026 to Dec 28, 2028
    v275
Show 29 earlier versionsHide 29 earlier versions
  1. Minor Enrollment target: 900 to 991
    • Interventions: Biospecimen Collection (Procedure), Laboratory Biomarker Analysis (Other), Questionnaire Administration (Other) to Biospecimen Collection (Procedure), Questionnaire Administration (Other)
    • Study description expanded, about 65 words
    • Study title expanded, about 3 words
    v269
  2. Notable Primary and study completion dates: Dec 31, 2022 to Feb 28, 2026v268
  3. Minor Site details revisedv264
  4. Minor Study site revisedv260
  5. Notable Trial status: Terminated to Active, Not Recruitingv259 Show 4 more changesShow less
    • Primary and study completion dates: May 13, 2020 to Dec 31, 2022
    • Enrollment target: 869 to 900
    • Start date: Jul 18, 2018 to Jul 2, 2018
    • Interventions: Biospecimen Collection (Procedure), Laboratory Biomarker Analysis (Other), Questionnaire Administration (Other)
  6. Stopped Trial status: Active, Not Recruiting to Terminated Sponsor's reason: NIH is not engaged in human subjects research
    • Primary and study completion dates changed from estimate of Dec 31, 2022 to May 13, 2020
    v258
  7. Minor Trial status: Enrolling by Invitation to Active, Not Recruitingv257
  8. Notable Enrollment target: 85 to 869
    • Start date: Jul 2, 2018 to Jul 18, 2018
    v254
  9. Minor Start date changed from estimate of Oct 23, 2018 to Jul 2, 2018v252
  10. Minor Start date: Oct 22, 2018 to Oct 23, 2018v251
  11. Minor Start date: Oct 19, 2018 to Oct 22, 2018v250
  12. Minor Start date: Oct 18, 2018 to Oct 19, 2018v249
  13. Minor Start date: Oct 17, 2018 to Oct 18, 2018v248
  14. Minor Start date: Oct 16, 2018 to Oct 17, 2018v247
  15. Minor Start date: Oct 15, 2018 to Oct 16, 2018v246
  16. Minor Start date: Oct 12, 2018 to Oct 15, 2018v245
  17. Minor Start date: Oct 11, 2018 to Oct 12, 2018v244
  18. Minor Start date: Oct 10, 2018 to Oct 11, 2018v243
  19. Minor Start date: Oct 9, 2018 to Oct 10, 2018v242
  20. Minor Start date: Oct 8, 2018 to Oct 9, 2018v241
  21. Minor Start date: Oct 5, 2018 to Oct 8, 2018v240
  22. Minor Start date: Oct 4, 2018 to Oct 5, 2018v239
  23. Minor Start date: Oct 3, 2018 to Oct 4, 2018v238
  24. Minor Start date: Oct 2, 2018 to Oct 3, 2018v237
  25. Minor Start date: Oct 1, 2018 to Oct 2, 2018v236
  26. Minor Start date: Sep 28, 2018 to Oct 1, 2018v235
  27. Minor Start date: Sep 27, 2018 to Sep 28, 2018v234
  28. Minor Start date: Sep 26, 2018 to Sep 27, 2018v233
  29. Minor Start date: Sep 25, 2018 to Sep 26, 2018v232
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Seropositivity
Timeframe: Up to 20 years after initial vaccination
Change in antibody levels
Timeframe: Between years 11 and 20 after initial vaccination
Proportion of individuals who serorevert
Timeframe: Between years 11 and 20 after initial vaccination

Arms and interventions

Observational (questionnaire, biospecimen collection)

Patients complete a short questionnaire regarding risk factors for HPV infection and undergo collection of blood samples for testing HPV16 and HPV18 levels on study.

Procedures: Biospecimen Collection

Other: Questionnaire Administration

Sites

1 site in 1 country

  • Agencia Costarricense de Investigaciones Biomédicas (ACIB)Liberia, Guanacaste Province, Costa Rica